Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth Considering

Source Summary

Abbott is upgraded to Buy ahead of Q2 2026 earnings: Exact Sciences deal boosts cancer diagnostics growth as 2026 guidance improves. Click to read more.